-
Mashup Score: 7STAND Trial: Crizanlizumab Shows No Superiority Over Placebo for Sickle Cell Disease - 4 month(s) ago
The phase 3 STAND study contrasts from the phase 2 SUSTAIN study results, highlighting the absence of superiority of crizanlizumab over placebo on key efficacy endpoints.
Source: www.hcplive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Since early in her higher education studies, Lucrèce Delicat-Loembet has found genetics fascinating. With sickle cell disease common in her home nation of Gabon, it was perhaps no surprise that this would be the focus of her career. Today, she has three vital elements to her work—both as a researcher and teacher at the Faculty of Science at the Masuku University of Science and Technology (USTM) in Franceville, Gabon, and as founding president of the non-governmental organisation (NGO) Sickle Cell Disease Organization of Gabon (SCDOGa).
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Why FDA approval of sickle cell gene therapy is a ‘big deal’ - 5 month(s) ago
Why the FDA’s approval of revolutionary sickle cell gene therapy is a ‘big deal’
Source: www.pbssocal.orgCategories: General Medicine News, PediatricsTweet
-
Mashup Score: 9SenatoItaliano - 6 month(s) ago
Canale YouTube ufficiale del Senato della Repubblica
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Potential Cure for Sickle Cell Clears Hurdle for Approval - 6 month(s) ago
FDA advisors suggest the benefits of gene therapy outweigh risks of off-target editing
Source: www.medpagetoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2
Sickle cell disease is the most common inherited pathological haemoglobinopathy. Over the past 30 years, disease-related morbidity and mortality have …
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Improving outcomes in sickle cell disease - 7 month(s) ago
Commissioners Dr Michael R DeBaun and Dr Dipty Jain, and Lwimba Kasongo, MPH, who has lived experience of sickle cell disease, outline some of the obstacles …
Source: www.youtube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Researchers reported that deferiprone safety and efficacy was comparable with deferoxamine for treating iron overload in pediatric patients, according to a post hoc analysis published in Pediatric Blood & Cancer. Researchers compared the safety and efficacy of defe riprone and deferoxamine in patients aged 17 years or younger with sickle cell disease or other anemias who participated in the phase IIIb/IV FIRST trial. Deferoxamine is injected subcutaneously while deferiprone is an oral agent. Children who
Source: docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 1Allogeneic haematopoietic stem-cell transplantation versus gene therapy for haemoglobinopathies - 7 month(s) ago
Timothy S Olson
Source: www.thelancet.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2BODHI • โพธิ์ (@bodhi.indy) • Instagram photo - 7 month(s) ago
43 likes, 2 comments – bodhi.indy on October 11, 2023: “𝙅𝙤𝙞𝙣 𝘽𝙊𝘿𝙃𝙄 𝙞𝙣 𝙎𝙪𝙥𝙥𝙤𝙧𝙩𝙞𝙣𝙜 𝘾𝙝�…”
Source: www.instagram.comCategories: Hem/Oncs, Latest HeadlinesTweet
https://t.co/MYjxPn34o7 Negative Phase 3 trial for Crizanlizumab (Adakveo made by Novartis ) for #sicklecell Looks like approval might be pulled in UK Will FDA follow or will it keep its approval based on Phase 2 Sustain trial Very expensive med